U.S. Stock News

In early February 2026, Phibro Animal Health reported second-quarter 2026 results showing sales of US$373.91 million and net income of US$27.46 million, alongside six‑month sales of US$737.8 million and net income of US$53.99 million, all significantly higher than a year earlier. At the same time, the company issued fiscal 2026 guidance calling for net sales of US$1.45–US$1.50 billion and diluted EPS of US$2.08–US$2.32, giving investors a clearer view of expected scale and profitability for...

Glaukos (GKOS) has drawn fresh attention after reporting fourth quarter and full year 2025 results, issuing 2026 sales guidance of US$600 million to US$620 million, and recording a US$112,867,000 intangible asset impairment. See our latest analysis for Glaukos. Despite the latest guidance and impairment announcement, Glaukos’ recent trading has been weaker, with a 1 month share price return of 11.31% and a 1 year total shareholder return decline of 30.28%. However, the 3 year total...

Despite announcing strong earnings, Vertex, Inc.'s ( NASDAQ:VERX ) stock was sluggish. Our analysis uncovered some...

On 10 February 2026, Americas Gold and Silver Corporation announced a definitive joint venture agreement with United States Antimony to build and operate a new antimony processing plant in Idaho’s Silver Valley, with Americas holding 51% and US Antimony 49% ownership. This partnership links Americas’ mine feed from the Galena Complex with US Antimony’s processing and marketing capabilities, creating a fully U.S.-based mine-to-finished antimony supply chain that could align with federal...

If you are wondering whether Avantor's share price now reflects good value or lingering risk, you are not alone. The stock recently closed at US$9.05, with returns of an 18.9% decline over 7 days, a 25.6% decline over 30 days, a 21.0% decline year to date, a 47.8% decline over 1 year, a 62.6% decline over 3 years, and a 67.7% decline over 5 years. Recent coverage of Avantor has focused on its role in the broader pharmaceuticals and biotech supply chain and how sentiment around the sector may...

S&P Global (NYSE:SPGI) announced a collaboration with Verisk to share climate catastrophe exposure data for financial and insurance clients. The company also released its 2026 Liquidity Outlook, focusing on credit market risks tied to private credit, technology sector issuance related to AI, and potential changes in Federal Reserve policy. S&P Global, known for its credit ratings, benchmarks, and risk analytics, is leaning further into climate and credit risk data as investors and lenders...

If you are wondering whether Expand Energy is still worth your attention at around US$102.75, the key question is how that price stacks up against the company’s underlying value. The stock has been relatively steady in the short term, with returns of 0.5% over the last 7 days and 2.9% over the last 30 days, while year to date it is down 6.4% and the 1 year return is a marginal 0.4%, set against a 46.1% 3 year return and a 195.9% 5 year return. Recent news coverage around Expand Energy has...

If you are wondering whether National Fuel Gas is still reasonably priced after its run, this breakdown will help you work out what you are really paying for today. The stock most recently closed at US$87.17, with reported returns of 2.7% over 7 days, 7.3% over 30 days, 6.2% year to date, 22.3% over 1 year, 70.9% over 3 years and 123.3% over 5 years. Recent coverage has focused on how National Fuel Gas fits into the wider US utilities sector and how investors are thinking about regulated...

Snowflake (NYSE:SNOW) has agreed a $200 million partnership with OpenAI to bring OpenAI models into its Cortex AI platform. The company launched Cortex Code, a coding agent aimed at helping developers build on Snowflake more efficiently. Snowflake also announced new enterprise AI deployments with clients including United Rentals and Wolfspeed. For investors watching NYSE:SNOW, this AI push lands at a time when the shares trade around $177.1 and recent returns have been mixed. The stock...

In February 2026, CBIZ, Inc. announced a new share repurchase program authorizing the buyback of up to 5,000,000 shares through March 31, 2027, funded by operating cash flow and its credit facility following the expiration of its prior plan. This renewed commitment to returning capital highlights management’s confidence in CBIZ’s cash generation and balance sheet flexibility even as it continues to fund growth initiatives. We’ll now examine how this newly authorized, debt-supported...

If you are wondering whether Jabil's current share price reflects its underlying value, this article will walk you through what the numbers actually say. Jabil shares last closed at US$257.40, with returns of a 0.6% decline over 7 days, 2.4% over 30 days, 7.1% year to date, 51.7% over 1 year and a very large gain over 5 years. Recent headlines around Jabil have focused on its position as a key manufacturing partner for large electronics and industrial customers, as well as ongoing portfolio...

Why Banc of California is on investors’ radar today Banc of California (BANC) is drawing attention after recent share price moves, with the stock last closing at $20.10. Investors are weighing this level against the bank’s current earnings profile and valuation signals. See our latest analysis for Banc of California. At the current share price of $20.10, Banc of California’s recent 18.93% 3 month share price return and 29.49% 1 year total shareholder return suggest momentum has improved...

If you are trying to figure out whether Ocular Therapeutix at around US$6.99 still offers value or has run its course, you are in the right place. The stock has recently been volatile, with a 22.6% decline over the last 7 days, a 38.0% decline over 30 days and a 40.9% decline year to date, while the 3 year return sits at 21.8%. Recent headlines around Ocular Therapeutix have focused on its position in ophthalmology and how its pipeline and products could shape future prospects. This helps...

HubSpot, Inc.'s ( NYSE:HUBS ) strong earnings report was rewarded with a positive stock price move. We did some digging...

Anterix Inc.'s ( NASDAQ:ATEX ) stock performed strongly after the recent earnings report. However, we think that...

In the last year, multiple insiders have substantially increased their holdings of aTyr Pharma, Inc. ( NASDAQ:ATYR...

Q2 Holdings, Inc.'s ( NYSE:QTWO ) earnings announcement last week was disappointing for investors, despite the decent...

Some Yum China Holdings, Inc. ( NYSE:YUMC ) shareholders may be a little concerned to see that the CEO & Executive...

Some TTM Technologies, Inc. ( NASDAQ:TTMI ) shareholders may be a little concerned to see that the Director, Thomas...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

AtriCure, Inc. recently reported its fourth quarter and full-year 2025 results, with quarterly revenue of US$140.5 million, a swing to net income of US$1.76 million, and substantially reduced full-year losses alongside 2025 revenue of US$534.53 million. Management also issued 2026 guidance calling for US$600 million to US$610 million in revenue and positive net income, while highlighting progress in key clinical programs and new product launches that could influence the company’s market...

Brookdale Senior Living (BKD) is back in focus as it prepares to release its Q4 2025 earnings after the market closes today, with investors watching revenue trends and loss expectations closely. See our latest analysis for Brookdale Senior Living. The share price has been strong heading into the release, with a 30 day share price return of 36.39% and a year to date share price return of 53.51%. At the same time, the 1 year total shareholder return of 213.96% and 3 year total shareholder...

If you are wondering whether Innodata's recent share price pulls you toward a bargain or a value trap, this article will walk through what the current market price might be saying about the stock. The share price closed at US$43.02, with returns of a 9.5% decline over 7 days, a 30.1% decline over 30 days and an 18.8% decline year to date. Over the past 3 years and 5 years, the returns are very large compared to the starting point. Over the past year, Innodata has also recorded a 25.9%...

Corteva (CTVA) is drawing fresh attention after leading Resurrect Bio’s US$8.1 million Series A round through its Corteva Catalyst platform. The move is aimed at supporting new crop protection traits and potential commercial partnerships. See our latest analysis for Corteva. Alongside the Resurrect Bio investment and a recently completed US$569.98 million share buyback, Corteva’s 30 day share price return of 8.49% and 90 day share price return of 16.81% suggest momentum has been building,...